Xequel Bio Is Committed To Developing Transformative Therapeutics For Inflammation And Injury Based Medical Conditions.

Xequel Bio is a clinical stage biopharmaceutical company developing dermatologic, ophthalmic, and pulmonary therapeutics utilizing our proprietary aCT1 technology platform. We are dedicated to developing drugs that will enable physicians to better manage a variety of indications involving inflammation and the body’s response to injury.

FirstString Research is now

New website coming soon. 

Read More >